Lewy body dementia
Resources for Patients and Caregivers
Lewy body dementia (LBD) is a disease associated with abnormal deposits of a protein called alpha-synuclein in the brain. These deposits, called Lewy bodies, affect chemicals in the brain whose changes, in turn, can lead to problems with thinking, movement, behavior, and mood.
Cluster Number:
Wiki Number: 26-Lewy Bodies Disorder/Dementia
Diagnosis:
US Patients: American actor and comedian Robin Williams committed suicide in 2014 with Parkinson’s and Lewy Bodies.
World Patients:
Sex Ratio:
Age Onset: after age 50 with life expectancy of 8 years after diagnosis
Brain Area: The SNCA gene encodes the alpha-synuclein protein which is a building-block of Lewy bodies.
Symptoms: acting out dreams, visual hallucinations, attention difficulties, slowness of movements
Progression: dementia and Parkinson’s patients may also be affected. Cause cognitive fluctuations.
Causes: clumps of protein form on brain neurons causing heart and digestive functions, low blood pressure and apathy.
Medications: several
Therapies: Cognitive training, deep-brain and transcranial direct current stimulations have been used.
Youtube Video: Lewy Body Disease
Amazon or Library Book:
A Caregiver’s Guide to Lewy Body Dementia
Click the book to link or buy from Amazon.
Support Group: lbda.org; 800-539-9767 (lewybodydementiaassociation)
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Manipulated mesenchymal stem cell therapy in the treatment of Parkinson's diseaseby Seyedeh Toktam Ekrani on December 19, 2024
Mesenchymal stem cell (MSC) therapy has been considered a promising approach for the treatment of Parkinson's disease (PD) for several years. PD is a globally prevalent neurodegenerative disease characterized by the accumulation of Lewy bodies and the loss of dopaminergic neurons, leading to severe motor and non-motor complications in patients. As current treatments are unable to halt the progression of neuronal loss and dopamine degradation, MSC therapy has emerged as a highly promising...
- Dementia with lewy bodies patients with high tau levels display unique proteome profilesby Sinead Greally on December 19, 2024
CONCLUSION: This molecular-level data supports the idea of neurodegenerative disease as a continuum of diseases with distinct PTM profiles DLBTau^(+) and DLBTau^(-) patients in comparison to AD. These findings further emphasize the importance of identifying specific and tailored therapeutic approaches targeting the involved proteopathies in the neurodegenerative disease spectrum.
- Assessment of cerebral perfusion alterations in dementia with Lewy bodies and Alzheimer's diseaseby Yanlai Xia on December 19, 2024
CONCLUSIONS: DLB demonstrates a different pattern of regional blood flow reduction and prolonged ATT, which is different from that in AD. ASL-derived parameters provide critical discriminative information for differentiating DLB and AD.
- Rapamycin Abrogates Aggregation of Human α-Synuclein Expressed in Fission Yeast via an Autophagy-Independent Mechanismby Yoshitaka Sugimoto on December 18, 2024
Aggregation of alpha-synuclein (α-Syn) is implicated in the pathogenesis of several neurodegenerative disorders, such as Parkinson's disease and Dementia with Lewy bodies, collectively termed synucleinopathies. Thus, tremendous efforts are being made to develop strategies to prevent or inhibit α-Syn aggregation. Here, we genetically engineered fission yeast to express human α-Syn C-terminally fused to green fluorescent protein (GFP) at low and high levels. α-Syn was localized at the cell tips...